ClinicalTrials.gg
RecruitingNCT06062953MEL-QUEUpdated Apr 24, 2025

Efficacy of Melatonin, Low-dose Quetiapine, or Placebo in Patients With Psychiatric Disorders and Comorbid Insomnia

A Phase 2/3 interventional study of Melatonin and Quetiapine in Psychiatric Disorders and Insomnia, sponsored by Lone Baandrup. Recruiting at 1 site in Denmark. Open to participants aged 16 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-24.

Primary conditionSleep Initiation and Maintenance DisordersRegistry: Mental DisordersReclassifiedWhy we changed it
Registry
Mental Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Sleep Initiation and Maintenance Disorders
Why
  1. The study's listed conditions name Sleep Initiation and Maintenance Disorders, a narrower term within Mental Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Lone Baandrup · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
16 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders — 8 open to participants now, 8 under way, 2 of them phase 3. Melatonin · Sleep Initiation and Maintenance Disorders.

Planned enrollment
3rd of 25
255 · median 59
Started
2023
with 1 other
Phase 2/3
3 of 25
1 open now
Registered
15th of 25
by date

Among the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 3 in phase 2/3, and was the 15th registered.

Sleep Initiation and Maintenance Disorders

2,734 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

8 of the 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About melatonin

Melatonin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 16 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing melatonin in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The goal of this investigator-initiated, randomized, blinded, 3-armed placebo-controlled, pragmatic, clinical superiority trial is to examine the efficacy of melatonin or low-dose quetiapine versus placebo for treatment of insomnia in patients with psychiatric disorders. The aims of the study are:

  • To examine the efficacy of melatonin or low-dose quetiapine versus placebo for treatment of insomnia
  • To examine how melatonin or low-dose quetiapine affects global symptom severity, sleep quality, psychosocial functioning and subjective well-being.

Participants will receive six weeks of treatment with either melatonin, quetiapine or placebo followed by a brief taper off.

03

Conditions studied

  • Psychiatric Disorders
  • Insomnia

Browse trials for

04

In context

Sleep Initiation and Maintenance Disorders Reclassified

2,734 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

This study's planned enrollment of 255 is above the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Compared within Sleep Initiation and Maintenance Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mental Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
16 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 16 to 64 years of age
  • ICD-10 diagnosis of a current or previous mental or behavioral disorder (F20-F69, F84, F90-95)
  • For the diagnoses F84 and F90 a previous period of treatment with melatonin is required
  • For the 16-17 years old: Non-pharmacological treatment options including sleep hygiene education, weighted blanket or other gravity products have been tested with insufficient effect
  • Self-reported sleep difficulties at least three times per week in the preceding 3 months
  • Insomnia Severity Index score ≥11
  • Women of : negative pregnancy test at baseline and use of highly effective measures

Exclusion criteria

Exclusion Criteria:

  • Current treatment with melatonin or quetiapine
  • Severe somatic comorbidity
  • ≥ 35 kg/m2
  • Breastfeeding
  • Alcohol and/or substance dependency within the last 3 months
  • Inadequate Danish language skills
  • Not able to make an
  • Increased cardiac risk as assessed by presence of cardiac risk factors, cardiac symptoms, or prolonged -interval at baseline
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
255 participants (estimated)

Study arms

  • Experimental
    Melatonin

    Drug: Melatonin

  • Experimental
    Quetiapine

    Drug: Quetiapine

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 3-9 mg flexible dosing before bed time

  • 50-150 mg flexible dosing before bed time

  • DrugPlacebo

    1-3 capsules flexible dosing before bed time

07

What researchers measure

Primary outcomes

  1. Insomnia severity

    Insomnia Severity Index, range 0-28, higher is worse

    Time frame: 6 weeks

Secondary outcomes

  1. Clinical global impression (CGI)

    Clinical global impression: Severity, range 0-7, higher is worse

    Time frame: 6 weeks

  2. Subjective sleep quality

    Pittsburgh Sleep Quality Index, range 0-21, higher is worse

    Time frame: 6 weeks

  3. Psychosocial functioning

    Personal and Social Performance Scale, range 1-100, higher is better

    Time frame: 6 weeks

  4. Patient-reported subjective well-being

    WHO-5 well-being index, range 0-100, higher is better

    Time frame: 6 weeks

Other outcomes

  1. Objective sleep quality (polysomnography)

    Total sleep time in minutes, higher is better

    Time frame: 6 weeks

  2. Circadian rhythmicity (actigraphy)

    Interdaily stability which quantifies the invariability from day to day, i.e., the predictability of the 24 h rest-activity pattern. This index will be 1 for perfect interdaily stability and thus lower values reflect higher variability between the observed days

    Time frame: 6 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Individual participant data will be available for meta-analysis. Proposals should be directed to: lone.baandrup@regionh.dk. To gain access, data requestors will need to sign a data access agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of planned primary, secondary and exploratory outcomes. There will be no end date for availability of data.

Access criteria: Meta-analytical purposes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Feb 2029, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2023
First posted
Oct 2, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06062953
Lead sponsor
Lone Baandrup
Collaborators
Danish Center for Sleep Medicine, Region Capital Denmark, Copenhagen Trial Unit, Center for Clinical Intervention Research, Mental Health Services in the Capital Region, Denmark
Responsible party
Lone Baandrup (Sponsor-investigator, University of Copenhagen) — Sponsor-investigator
First posted
Oct 2, 2023
Start date
Sep 18, 2023
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 24, 2025

Study contacts

Lone Baandrup, MD
Contact
lone.baandrup@regionh.dk
+4591165903
Lone Baandrup, MD
principal investigator · Mental Health Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Melatonin · Quetiapine

Start the discussion